Psychotic and neurodevelopmental disorders: schizophrenia, ADHD, autism spectrum
Anchor (Master): Andreasen, N. C. — Brave New Brain (2001)
Intuition Beginner
Schizophrenia is a severe disorder that affects about one in every hundred people. Its symptoms split into three groups. Positive symptoms are experiences added that should not be there: hallucinations, delusions, and disorganized speech. Negative symptoms are capacities missing that should be present: flat emotion, social withdrawal, and lack of drive. Cognitive symptoms are problems with attention, memory, and planning. Schizophrenia is highly heritable, with genes explaining roughly 80% of the risk, yet environment also shapes who develops it [Myers and DeWall 2021].
Schizophrenia runs in families, but no single gene causes it. Twin studies put its heritability near 80%, among the highest for any psychiatric disorder, yet identical twins often differ — one affected, the other not — which shows environment still matters. The leading explanation points to dopamine, a chemical messenger in the brain. Too much dopamine activity in certain circuits is linked to hallucinations and delusions, and antipsychotic drugs that quiet this activity relieve those symptoms. The drugs fall short on the withdrawn, dulled, and disorganized features, which is why schizophrenia remains so hard to treat [Andreasen 2001].
ADHD, autism, and neurodiversity Beginner
Attention-deficit/hyperactivity disorder, or ADHD, affects an estimated 5 to 10 percent of children. Its hallmarks are persistent inattention, hyperactivity, and impulsivity that interfere with school, work, and relationships. A child with ADHD may struggle to finish tasks, sit still, wait their turn, or resist acting on sudden urges. The symptoms begin in childhood, often before age seven, and many children carry them into adulthood. Stimulant medications such as methylphenidate, paradoxically, calm rather than excite these patients, by boosting dopamine and norepinephrine in the prefrontal cortex and strengthening self-control.
Autism spectrum disorder centers on two difficulties: trouble with social communication and a strong preference for restricted, repetitive behaviors. An autistic child may avoid eye contact, miss social cues, or struggle with back-and-forth conversation, while also insisting on sameness, following rigid routines, or developing intense interests in narrow topics. Sensory differences are common — certain sounds, lights, or textures can be overwhelming or barely noticed. Autism varies enormously in severity, which is why clinicians speak of a spectrum, and why two people with the same diagnosis can look completely unlike each other [Gleitman 2011].
The neurodiversity movement reframes autism and ADHD as natural variations in how human brains work, not defects to be repaired. Advocates argue that society should accommodate neurological differences, much as it accommodates left-handedness or different learning styles, rather than insisting everyone conform to one norm. This view does not deny that these conditions can bring real hardship, especially when support is lacking. It does dispute the assumption that the goal must always be to make autistic or ADHD minds more typical, and it has reshaped how many clinicians, educators, and autistic people themselves describe these conditions.
Visual Beginner
The diagram maps the three disorders against the shared explanatory layers — dopaminergic and glutamatergic circuitry, developmental pruning, cortical maturation, and polygenic risk — that the intermediate and master tiers develop.
Check your understanding Beginner
Formal definition Intermediate
The DSM-5-TR places schizophrenia and other psychotic disorders in one chapter and groups ADHD and autism under the neurodevelopmental disorders, reflecting a shared view that all three are rooted in altered brain development [DSM-5-TR 2022].
Schizophrenia. Criterion A requires two or more of the following, each present for a significant portion of time during a one-month period (or less if successfully treated), with at least one being item 1, 2, or 3: (1) delusions, (2) hallucinations, (3) disorganized speech, (4) grossly disorganized or catatonic behavior, (5) negative symptoms such as diminished emotional expression or avolition. Criterion B requires a marked drop in functioning in one or more major areas — work, interpersonal relations, or self-care — relative to the premorbid level. Criterion C requires continuous signs of disturbance persisting for at least six months, a period that must include at least one month of active-phase symptoms and may include prodromal or residual periods. Criteria D through F rule out schizoaffective disorder and mood disorders with psychotic features, substance or medical causes, and, when there is a history of autism or a communication disorder of childhood onset, require that prominent delusions or hallucinations be present for at least one month. The DSM-5 dropped the historical subtypes — paranoid, disorganized, catatonic, undifferentiated, residual — because they were poorly stable and weakly predictive, replacing them with a spectrum framing and dimensional ratings of symptom severity.
Positive symptoms are additions to normal experience. Hallucinations are false sensory perceptions, auditory being by far the most common in schizophrenia, typically experienced as voices commenting, commanding, or conversing. Delusions are fixed false beliefs held against contrary evidence; persecutory, grandiose, and ideas of reference are frequent subtypes. Disorganized thinking shows up as loose associations, derailment, or, at the extreme, word salad. Disorganized behavior ranges from aimless agitation to catatonia, marked by mutism, posturing, or waxy flexibility.
Negative symptoms are absences of normal function: blunted or flat affect, alogia (poverty of speech), avolition (reduced drive to initiate purposeful activity), asociality, and anhedonia. These are the most disabling for long-term outcome and the least responsive to current medication. Cognitive symptoms — deficits in executive function, working memory, attention, and processing speed — track the negative symptoms in their resistance to treatment and their impact on functional recovery.
Course. Schizophrenia typically unfolds in phases: a prodromal period of declining function, social withdrawal, and attenuated symptoms; an active phase of frank psychosis; and a residual phase in which acute positive symptoms recede but negative and cognitive impairments persist. Onset is usually in late adolescence or early adulthood, earlier in men than in women on average.
Attention-deficit/hyperactivity disorder. Criterion A requires six or more symptoms of inattention (for example, careless mistakes, difficulty sustaining attention, not listening, failing to finish tasks, disorganization, avoiding effortful tasks, losing things, distractibility, forgetfulness) or six or more symptoms of hyperactivity-impulsivity (fidgeting, leaving one's seat, running or climbing inappropriately, inability to play quietly, being "on the go," talking excessively, blurting answers, difficulty waiting, interrupting). For adults and adolescents 17 and older, the threshold drops to five. Criterion B requires several symptoms before age 12. Criterion C requires impairment in two or more settings. Criterion D requires clear interference with functioning, and Criterion E excludes other causes. Symptoms must persist for at least six months. ADHD persists into adulthood in roughly 60% of cases.
Autism spectrum disorder. Criterion A requires persistent deficits in social communication and social interaction across multiple contexts, spanning social-emotional reciprocity, nonverbal communicative behaviors, and the ability to develop, maintain, and understand relationships. Criterion B requires restricted, repetitive patterns of behavior, interests, or activities, with at least two of four: stereotyped or repetitive movements, speech, or use of objects; insistence on sameness, inflexible adherence to routines, or ritualized patterns; highly restricted, fixated interests of abnormal intensity; and hyper- or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment. Criterion C requires onset in the early developmental period. Criterion D requires clinically significant impairment. Criterion E excludes intellectual disability alone. Severity is rated on three levels — requiring support, requiring substantial support, requiring very substantial support — specified separately for the social-communication and restricted-behavior domains.
Early signs of autism often emerge between 12 and 18 months: failure to establish joint attention, no response to name, absent or reduced pretend play, and, in a subset of children, a regression in language and social skills after apparently normal early development.
Prevalence and heritability. Schizophrenia affects roughly 0.3 to 1 percent of the population worldwide, with a lifetime prevalence near 1 percent and heritability of approximately 80 percent — among the highest for any psychiatric diagnosis. ADHD affects an estimated 5 percent of children, with heritability of 70 to 80 percent. Autism spectrum disorder has a prevalence of roughly 1 to 2 percent; a known genetic cause can be identified in 15 to 20 percent of cases (fragile X syndrome, tuberous sclerosis, SHANK3 mutations, copy number variants), with the remainder attributable to polygenic risk and gene-environment interaction [Gleitman 2011].
Key mechanism: the dopamine hypothesis and neurodevelopment Intermediate
The dopamine hypothesis is the oldest and most durable mechanistic account of schizophrenia. Its original form, built on two findings — that amphetamine, which releases dopamine, can induce a paranoid psychosis, and that antipsychotic drugs block dopamine D2 receptors — proposed that schizophrenia reflects excess dopaminergic activity. The modern refinement, due largely to the work gathered in Andreasen's synthesis and later formalized by Howes and Kapur, specifies where the excess lies. Mesolimbic dopamine hyperactivity, projecting from the ventral tegmental area to the nucleus accumbens and limbic targets, is thought to drive the positive symptoms. Mesocortical dopamine hypoactivity, projecting to the prefrontal cortex, is thought to underlie the negative and cognitive symptoms. The same drug can fail to treat the latter because boosting or blocking a single receptor cannot correct a pathway-specific imbalance that runs in opposite directions [Andreasen 2001].
The dopamine account is necessary but not sufficient. Three further findings stretch it toward a broader neurodevelopmental model.
The glutamate hypothesis. Drugs that block NMDA glutamate receptors — ketamine and PCP — produce a symptom profile in healthy volunteers that resembles schizophrenia more closely than amphetamine does, including negative and cognitive symptoms, not merely positive ones. This NMDA-hypofunction model suggests that glutamatergic dysregulation lies upstream of the dopamine abnormality, and that the dopaminergic excess is a downstream consequence rather than the root cause.
Structural brain changes. Imaging consistently shows enlarged lateral and third ventricles and reduced gray matter in people with schizophrenia, with the loss concentrated in temporal and frontal regions. Critically, these changes appear early and follow a trajectory more consistent with aberrant neurodevelopment than with neurodegeneration: they are present at or before the first psychotic episode and progress most rapidly in the years immediately surrounding onset, then slow. Brains of people with schizophrenia are not steadily decaying; they developed differently from the start.
Genetics and prenatal risk. Schizophrenia's 80 percent heritability is polygenic: no single gene accounts for much of the risk. Candidate genes such as DISC1, neuregulin 1, and dysbindin contribute small effects, and genome-wide association studies implicate many variants of tiny individual weight, gathered into polygenic risk scores. The strongest single known risk factor is the 22q11.2 deletion (DiGeorge syndrome): roughly 25 to 30 percent of individuals with this deletion develop schizophrenia. Prenatal and perinatal stressors — maternal infection during pregnancy, prenatal famine, obstetric complications, and heavy cannabis use in early adolescence — raise risk modestly but reliably, consistent with a model in which an inherited predisposition is amplified by environmental hits to a developing brain.
ADHD neurobiology. ADHD's mechanism converges on the prefrontal cortex and its catecholaminergic inputs. The prefrontal cortex depends on optimal levels of dopamine and norepinephrine to sustain working memory, attention, and inhibitory control; too little weakens signal, too much adds noise. Stimulants raise these neurotransmitters into the effective range, which is why the same drug that activates most people steadies those with ADHD. Functional imaging shows reduced prefrontal and striatal activation during inhibitory tasks, and structural studies find subtle cortical differences consistent with delayed maturation rather than a lesion.
Autism genetics. Autism's identifiable genetic causes — fragile X, tuberous sclerosis, SHANK3 — converge on genes governing synaptic formation and function, which is why the condition is understood as a disorder of early brain wiring. The remaining cases are polygenic, and the recurrence risk within families is markedly elevated relative to the general population.
Bridge. Dopamine, glutamate, structural, genetic, and prenatal findings are not rival explanations but levels of one neurodevelopmental story. The master tier unpacks each level: the revised Howes-Kapur dopamine synthesis model, the C4 synaptic-pruning hypothesis, the delayed cortical maturation trajectory of ADHD, and the cognitive and social-cognitive theories of autism — together with the treatments and the political-philosophical reframing carried by the neurodiversity movement.
Exercises Intermediate
Advanced models and treatments Master
The revised dopamine hypothesis
Howes and Kapur's reconceptualization (2009) shifted the dopamine hypothesis from a story about receptor blockade to one about presynthetic synthesis. PET studies using radiolabelled L-DOPA show that people with schizophrenia and those at clinical high risk for psychosis have elevated presynaptic dopamine synthesis in the dorsal striatum — not merely altered receptor density. Dopamine, on this account, is the "final common pathway" through which diverse upstream causes (genetic loading, prenatal insult, glutamatergic dysregulation, stress) converge to produce the psychotic phenotype. The reformulation explains why drugs from different classes, hitting different targets, all end up blocking D2 receptors: they act at the end of the funnel. It also reframes treatment resistance: if the upstream drivers are strong enough, downstream blockade cannot fully normalize transmission.
Glutamate, synaptic pruning, and the complement cascade
The glutamate hypothesis gained traction because the NMDA-antagonist model (ketamine, PCP) reproduces the full triad of positive, negative, and cognitive symptoms in a way dopamine agonists do not. Sekar and colleagues (2016) provided a genetic anchor: variation in the complement component 4 (C4) gene locus is associated with schizophrenia risk, and C4 mediates synaptic pruning — the developmental process by which excess synapses are eliminated during adolescence. The hypothesis is that excessive C4-driven pruning in adolescence strips away too many cortical synapses, and the resulting connectivity loss underlies the onset of psychosis in the late-second-decade window that schizophrenia characteristically occupies. This is a developmental, not degenerative, account: the brain is not deteriorating in adulthood; it was over-pruned a decade earlier. Mismatch negativity (MMN), an event-related potential indexing pre-attentive sensory prediction error, is reliably reduced in schizophrenia and tracks the prediction-error account of delusion formation — a candidate biomarker linking glutamatergic function to psychotic phenomenology.
Antipsychotic pharmacology
The first generation — typical antipsychotics such as chlorpromazine and haloperidol — are D2 antagonists. They are effective against positive symptoms but carry a substantial side-effect burden: extrapyramidal symptoms (parkinsonism, akathisia, acute dystonia) from nigrostriatal blockade, elevated prolactin from tuberoinfundibular blockade, and, with chronic use, tardive dyskinesia, an often irreversible movement disorder. The second generation — atypical antipsychotics such as clozapine, risperidone, and olanzapine — combine D2 antagonism with 5-HT2A antagonism, which reduces (though does not eliminate) the extrapyramidal burden. Clozapine is the most effective antipsychotic available and the standard for treatment-resistant schizophrenia, but it carries a roughly 1 percent risk of agranulocytosis, requiring mandatory blood monitoring. Attempts to target the glutamatergic system directly — glycine-site NMDA modulators such as glycine, D-serine, and sarcosine — produced disappointing results in large trials, a sobering reminder that a compelling hypothesis does not guarantee a translatable drug. Across medications, the negative and cognitive symptoms remain undertreated; this is the largest unmet need in schizophrenia therapeutics.
Early intervention and the duration of untreated psychosis
Epidemiological work established that a longer duration of untreated psychosis (DUP) — the gap between onset of frank psychosis and the start of treatment — predicts worse long-term outcome, including greater symptom severity and poorer functional recovery. First-episode psychosis teams and early intervention services aim to compress this interval, and trials show they improve outcomes over standard care. Whether DUP is a causal driver (psychosis is neurotoxic if untreated) or a marker of an already more severe illness remains debated; the clinical implication is the same — treat early.
ADHD: executive function and dual-pathway models
Barkley's hybrid model of executive functions locates the core deficit in behavioral inhibition — the ability to interrupt a prepotent response, resist interference, and hold an action in abeyance. From this primary deficit cascade the other executive functions: working memory, self-regulation of affect and motivation, internalization of speech, and reconstitution (the analysis and synthesis of behavior). ADHD, on this account, is a disorder of inhibition-mediated self-regulation rather than of inattention narrowly construed.
Sonuga-Barke's dual-pathway model offers a complementary framing. ADHD arises from two partially independent deficits: an executive-dysfunction pathway (poor inhibitory control) and a delay-aversion pathway, in which the subjective cost of waiting is elevated, driving choices that favor immediate over delayed reward. The two pathways account for the heterogeneity of ADHD: some children are chiefly impulsive in the inhibitory sense; others are chiefly intolerant of delay.
Shaw and colleagues (2007) traced the neurodevelopmental trajectory using longitudinal cortical-thickness mapping. Children with ADHD show a cortical maturation curve shifted roughly two to three years later than controls, most pronounced in the prefrontal regions governing attention and control. The brains mature in the same sequence, just behind schedule — consistent with a delay rather than a fixed deficit, and congruent with the partial symptomatic improvement many experience with age. Long-term outcomes track the domains you would expect: educational attainment, occupational functioning, driving safety, and substance-use risk remain elevated through adulthood for a substantial minority.
Autism: cognitive and social-cognitive theories
Baron-Cohen's theory-of-mind account proposed that the core cognitive feature of autism is impaired mindblindness — difficulty representing the mental states (beliefs, intentions, knowledge) of others. The false-belief-task literature showed that autistic children pass these milestones later, or not at all, and the deficit scales with the severity of the social-communication impairment. Baron-Cohen later generalized this into the empathizing-systemizing theory: autistic profiles show reduced empathizing alongside intact or enhanced systemizing — the drive to analyze or construct rule-governed systems, which accounts for the pattern of intense, structured interests.
Executive dysfunction accounts of autism overlap heavily with ADHD: rigid, repetitive behavior and insistence on sameness can be read as failures of cognitive flexibility and set-shifting. Weak central coherence, proposed by Frith, takes the opposite emphasis: the autistic cognitive style is characterized by superior local, detail-focused processing at the expense of global meaning-making. This is not a deficit but a processing bias — it explains both the strengths (block design, embedded figures, attention to detail) and the difficulties (grasping gist, context, the social whole). Sensory processing differences — hyper- and hyporeactivity to sound, light, touch, and texture — are now recognized as a core diagnostic feature rather than a peripheral complaint, and they reshape the clinical environment (lighting, noise, predictability) toward accommodation. Epigenetic regulation and the gut-brain axis are active research frontiers, though neither yet yields a treatment.
The neurodiversity movement
Singer (1998) coined "neurodiversity" to argue that neurological variation, including autism, is a natural dimension of human difference to be respected rather than a pathology to be eliminated. The movement, carried by organizations such as the Autistic Self Advocacy Network (ASAN), draws on the social model of disability: disability arises from the mismatch between a person's traits and an unaccommodating environment, not solely from the traits themselves. On this view, an autistic person's difficulties in a fluorescent, unpredictable, small-talk-driven office are partly produced by the office, not wholly by the autism.
The movement has sharpened several contested issues. Applied behavior analysis (ABA), the most widely prescribed early intervention for autism, is denounced by many autistic self-advocates as compliance training that suppresses harmless behavior and traumatizes the child; practitioners defend it as evidence-based skill-building. The dispute is not about whether autistic children benefit from support but about who defines the goals and what counts as success. Identity-first language ("autistic person") is preferred by much of the self-advocate community over person-first language ("person with autism"), on the grounds that autism is integral to identity rather than an appended condition. The terms neurodivergent and neurotypical mark the variation without pathologizing it, and the framing intersects with broader disability studies, civil-rights theory, and the ethics of normalization.
Synthesis. The dopaminergic, glutamatergic, pruning, cortical-maturation, cognitive, and social models operate at different levels of a layered system. Schizophrenia reads as a neurodevelopmental disorder whose psychotic surface is dopaminergic and whose roots lie in early wiring and adolescent pruning. ADHD reads as a maturation-delay disorder of inhibition and reward. Autism reads as a wiring-difference disorder of social cognition and processing style. The neurodiversity movement does not refute the neuroscience; it reframes the values that determine what neuroscience findings are for.
Connections to other disciplines Master
Psychotic and neurodevelopmental disorders sit at the intersection of neuroscience, genetics, pharmacology, developmental psychology, and the philosophy and politics of disability. The dopaminergic and glutamatergic circuitry connects this unit directly to the neuroscience chapters (29.02), particularly the neurotransmitter-systems and brain-regions units. The cortical-maturation and pruning material builds toward the developmental-psychology lifespan unit (29.06.01) and the cognitive-development unit (29.06.02), where the trajectory of brain maturation returns as the substrate of developmental change. The theory-of-mind material on autism reaches back to cognitive development as well: the false-belief milestone is the same construct studied in typical development, here read as delayed or absent.
The pharmacology — D2 antagonism, stimulant and non-stimulant ADHD medications, clozapine monitoring — connects to the therapy and treatment unit (29.10.01), where the evidence base for pharmacotherapy and the common-factors debate are taken up in full. The early-intervention and DUP findings connect to health-services research and to public health, raising the question of how detection and access shape outcome. The genetic material — polygenic risk, 22q11, SHANK3 — connects to behavior genetics and to the prenatal and obstetric risk literature.
The neurodiversity material connects outward in a different direction: to cross-cultural and indigenous psychology (29.12), where the construction of normalcy varies; to the ethics of normalization and the social model of disability; and to the diagnostic-validity debates of the disorders-introduction unit (29.09.01). The schizophrenia diathesis-stress model is continuous with the vulnerability models of the mood and anxiety disorders (29.09.02, 29.09.03), and the dopamine, glutamate, and HPA axes recur across all of them — a recurring signal that the major psychiatric categories share more underlying circuitry than their separate diagnostic chapters suggest.
Historical and philosophical context Master
The modern concept of schizophrenia descends from Emil Kraepelin's 1896 delineation of dementia praecox, which he separated from manic-depressive illness by its deteriorating course and early onset. Eugen Bleuler renamed it schizophrenia in 1911, from the Greek for "split mind" — referring not to a split between personalities (a persistent popular confusion) but to a splitting of the associative threads of thought. Bleuler broadened Kraepelin's concept to include less deteriorating cases, a latitude that swelled the diagnosis in the mid-twentieth century and set up the diagnostic-reliability problems that catalyzed the DSM-III revolution of 1980 [Gleitman 2011].
The dopamine hypothesis emerged from two twentieth-century threads: the observation that amphetamine abusers developed paranoid psychosis, and the discovery that the first effective antipsychotics, chlorpromazine and haloperidol, blocked dopamine receptors. Arvid Carlsson's work on dopamine as a neurotransmitter earned him a share of the 2000 Nobel Prize and anchored the pharmacological era of schizophrenia treatment. The introduction of clozapine in the 1970s, and the atypicals that followed in the 1990s, expanded the armamentarium but did not resolve the core problem — negative and cognitive symptoms remain poorly treated, and the pharmacological ceiling has changed less than the marketing of "second-generation" drugs implied.
Autism's history runs parallel and instructive. Leo Kanner (1943) and Hans Asperger (1944) independently described the condition. For decades the refrigerator mother theory, popularized by Bruno Bettelheim in the 1950s and 1960s, blamed cold, rejecting parenting — a claim with no empirical support that inflicted immense harm on a generation of parents. Bernard Rimland's Infantile Autism (1964) and the subsequent twin studies of Folstein and Rutter established autism's organic, highly heritable basis, and the theory was abandoned. Asperger's account was absorbed into the DSM-IV as Asperger's disorder in 1994, then folded into the single autism spectrum diagnosis in DSM-5 (2013) — a consolidation that remains debated within both clinical and advocacy communities. ADHD's lineage runs from George Still's 1902 lectures on "defective moral control" through Charles Bradley's 1937 discovery that stimulants calmed behaviorally disturbed children, to its current status as the most pharmacologically treated childhood psychiatric diagnosis.
The neurodiversity movement is the youngest strand and the one with the deepest philosophical reach. Singer's 1998 thesis and the founding of ASAN reframed the autism conversation around self-advocacy and civil rights. The movement presses on a question that the neuroscience cannot answer alone: given that we can identify neurological differences, which of them warrant intervention, and on whose authority? The honest position is that the medical and social models describe the same reality from two standpoints, and that neither alone yields a complete ethics. A neurobiological account of schizophrenia or autism tells us what is happening; it does not, by itself, tell us what to do about it.
Philosophically, schizophrenia raises the question of the self: if hallucinations and delusions are generated by one's own brain, in what sense are they one's own experiences? The clinical reality — that people with psychosis often recognize their voices as alien even while unable to stop them — suggests a fragmentation of selfhood rather than its loss, and it grounds the distinction between psychosis and insight that treatment depends on. Autism and ADHD raise a different question: where does difference end and disorder begin? The neurodiversity movement argues that the line is drawn as much by social convention as by biology, and that the drawing is a moral and political act, not a neutral observation.
Bibliography Master
American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text revision). Author.
Andreasen, N. C. (2001). Brave New Brain: Conquering Mental Illness in the Era of the Genome. Oxford University Press.
Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III — The final common pathway. Schizophrenia Bulletin, 35(3), 549-562.
Kapur, S. (2003). Psychosis as a state of aberrant salience. American Journal of Psychiatry, 160(1), 13-23.
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., et al. (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530(7589), 177-183.
Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Archives of General Psychiatry, 51(3), 199-214.
Barkley, R. A. (1997). ADHD and the Nature of Self-Control. Guilford Press.
Sonuga-Barke, E. J. S. (2003). The dual pathway model of AD/HD: An elaboration of neuro-developmental characteristics. Neuroscience & Biobehavioral Reviews, 27(7), 593-604.
Shaw, P., Eckstrand, K., Sharp, W., Blumenthal, J., Lerch, J. P., Greenstein, D., et al. (2007). Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proceedings of the National Academy of Sciences, 104(49), 19649-19654.
Baron-Cohen, S. (1995). Mindblindness: An Essay on Autism and Theory of Mind. MIT Press.
Baron-Cohen, S. (2009). Autism: The empathizing-systemizing (E-S) theory. Annals of the New York Academy of Sciences, 1156, 68-80.
Frith, U. (1989). Autism: Explaining the Enigma. Blackwell.
Happé, F., & Frith, U. (2006). The weak coherence account: Detail-focused cognitive style in autism spectrum disorders. Journal of Autism and Developmental Disorders, 36(1), 5-25.
Singer, J. (1999). "Why can't you be normal for once in your life?" From a problem with no name to the emergence of the neurodiversity movement. Disability Studies Quarterly, 19(4).
Kanner, L. (1943). Autistic disturbances of affective contact. Nervous Child, 2, 217-250.
Bleuler, E. (1911). Dementia Praecox oder die Gruppe der Schizophrenien. Deuticke.
Gleitman, H., Gross, J., & Reisberg, D. (2011). Psychology (8th ed.). W. W. Norton.
Myers, D. G., & DeWall, C. N. (2021). Psychology (13th ed.). Worth Publishers.